• YAKHAK HOEJI
• /
• v.51 no.6
• /
• pp.402-408
• /
• 2007

The aim of this study was to evaluate the effect of menstration among the influencing factors for the GnRH agonist (as G: depot goserelin 3.6 mg) therapy prior to the planned myomectomy for women who wanted to preserve their fertility. We reviewed total 48 patients. with the G therapy prior to the planned myomectomy from August 1st, 2005 to August 31st, 2006. The patients were classified by the G group (n=28) and the immediate surgery (as S) group (n=20). The G group (n=19) underwent the G therapy for 3 month courses, and then the efficacy was evaluated by menstruation and the myoma volumes. In the G group (n=19), therapy was effective, and the mean age was $32.4{\pm}6.5$ years. After the completion of G therapy, the mean volume of the myoma by ultrasonography was reduced to $85.2{\pm}71.2cm^3$ comparing of $430.6{\pm}248.8cm^3$ at first visit. The 11 patients had menstruation and the rest 8 patients with amenorrhea had less reduced volume of the myoma ($124.05{\pm}79.85cm^3\;v.s.\;329.41{\pm}234.0cm^3$ p<0.05). In the immediate S group, the myoma volumes by sonography was also checked for accuracy (${\alpha}=1.0$). As the result, the initial myoma volume had the positive correlations to the effectiveness with G therapy. However, the occurrence and frequency of the menstruation during the G therapy had a negative correlation. In conclusion, the use of G prior to the planned myomectomy was effective in reducing myoma volume and the menstruation.

• Journal of Breast Disease
• /
• v.6 no.2
• /
• pp.46-51
• /
• 2018

Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

• Clinical and Experimental Reproductive Medicine
• /
• v.24 no.2
• /
• pp.179-185
• /
• 1997

$23{\sim}40$세 (평균 연령 31.6세)의 자궁내막증 환자35명 (1기 7명, 2기 7명, 3기 14명, 4기 7명)을 대상으로 gonadotropin-releasing hormone agonist (Goserelin) 3.6 mg을 한달 간격으로 6개월 복부의 피하에 이식한 후 자궁내막증에 대한 치료 효과와 부작용을 알아보기 위하여 매달 호르몬 검사와 증상에 대한 설문조사를 시행하였다. 투여 1개월 후 혈청 estradiol농도는 30 pg/mL이었고 이후 치료중 $10{\sim}20$ pg/mL를 유지하였으며 투여를 중간한 1개월 후 50 pg/mL로 증가하였다. 혈청 LH농도는 치료 중 유의하게 감소하였으며 투여를 중단한 후 증가하였다. FSH는 투여 1개월 후 감소하였으나 2개월후부터 계속 치료전과 같은 농도를 유지하였다. 혈청 CA-125치는 19명중 10명에서 치료전에 35 mIU/mL이상으로 증가되었으며 치료 2개월 후부터 모두 정상으로 감소되었다. 월경곤란증은 치료 3개월째 완전히 소실되었고 성교통은 치료가 끝날 때까지 20%의 환자에서 지속되었다. 백혈구수, 혈색소, 전해질, 단백질, 빌리루빈 및 간효소는 치료 중 모두 정상이었다. 혈압과 체중도 치료전, 치료중에 변화가 없었다. 투여후 86%의 환자가 안면홍조를 63%에서 질건조증을 20%가 두통, 우울을 호소하였다. 이와 같은 부작용은 투여를 중단한 1개월 후 모두 소실되었으며 부작용 때문에 투여를 중단한 예는 없었다. 이상의 결과로 GnRH-a는 난소의 estradiol생산을 완벽하게 중단시키고 골반증상을 완하시켜 자궁 내막증 치료에 효과적이라고 사료되며 안면홍조와 같은 부작용의 빈도가 높기 때문에 향후 호르몬 보충요법을 병행하는 것이 바람직 하다고 사료된다.